USPTO serial 88252188
Reviewed by CopyMark Law Group
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Palo Alto, CA
Palo Alto, CA
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals, namely, pharmaceutical preparations and substances for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical and veterinary preparations namely, prescription and non-prescription medicines in the form of pills, tablets, capsules, powders, syrups, sprays, gels, creams, caplets, liquid drops, sachets, and solutions for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; sanitary preparations for medical purposes; dietetic food and beverages adapted for medical or veterinary use; dietary supplements for humans and animals; medical and surgical plasters; materials for dressings, namely, sterilized dressings, burn dressings, wound dressings, medical dressings, and surgical dressings; material for stopping teeth, dental wax; disinfectants; ointments for pharmaceutical purposes, namely, antibiotic ointments, anti-fungal ointments, anti-inflammatory ointments, analgesic ointments, hemorrhoidal ointments, medicated ointments for treating dermatological conditions, and anti-itch ointments; ointments for pharmaceutical purposes, namely, medicated ointments for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; lotions for pharmaceutical purposes, namely, medicated lotions for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; lotions for pharmaceutical purposes, namely, pharmaceutical skin care lotions, antibiotic lotions, medicated aftershave lotions, medicated sunburn lotions, anti-fungal lotions, medicated lotions for treating dermatological conditions; Pharmaceutical skin lotions; balms for medical purposes | ACTIVE | — |
| 010 | Surgical instruments and apparatus; medical and veterinary apparatus and instruments for diagnosing, examining, treating, and monitoring viral, infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; dental apparatus and instruments, namely, dental picks, dental caps, dental inlays, dental onlays, dental burrs, dental bridges, dental mirrors, dental drills, dental prostheses, dental gloves, dental syringes, dental bite trays, oral irrigators, teeth protectors for dental purposes, X-ray apparatus for dental imaging; medical apparatus and instruments, namely, medical imaging apparatus; medical apparatus for facilitating the inhalation of pharmaceutical preparations; inhalers for medical use; cups for dispensing medicine; testing apparatus for medical purposes, namely, apparatus for diagnosing, examining, and monitoring viral, infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders | ACTIVE | — |
| 020 | Containers, not of paper or metal, for storage or transport; commercial dispensers for pills or capsules, sold empty; plastic medication containers for commercial use; commercial medical storage apparatus, namely, plastic pill dispensers, plastic pill containers, medication cases, and non-metal plastic boxes for storing pills and medication, sold empty | ACTIVE | — |
| 021 | Personal dispensers for pills or capsules for domestic use; personal medical storage apparatus, namely, plastic pill dispensers, plastic containers for storing and organizing medications and vitamins, and non-metal boxes for storing pills; lotion containers sold empty for domestic use | ACTIVE | — |
| 039 | Transport of goods; packaging and storage of goods; delivery of goods; delivery of goods by mail order; distribution services, namely, delivery of prescription medication; packaging of medication for others | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 9, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 9, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 10, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 9, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jun 1, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 1, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 13, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 13, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 13, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 10, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 10, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 10, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 10, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 10, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 23, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 19, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Nov 19, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Nov 19, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 23, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 3, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 1, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 1, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jun 1, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 26, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 24, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 24, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 24, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 29, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 27, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 27, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 27, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 3, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 8, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 8, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 18, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 5, 2019 | ALIE | ASSIGNED TO LIE | — |
| Aug 29, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 29, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 29, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 29, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 29, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 6, 2019 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Aug 2, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 31, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 30, 2019 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jul 30, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 30, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 30, 2019 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Jul 30, 2019 | EAAU | TEAS AMENDMENT OF USE RECEIVED | — |
| Feb 4, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 29, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 28, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 10, 2019 | NWAP | NEW APPLICATION ENTERED | — |